- Home
- LVLU vs XLO Comparison
LVLU vs XLO Comparison
Compare LVLU & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | XLO |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1M | 41.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LVLU | XLO |
|---|---|---|
| Price | $5.18 | $0.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | $2.00 |
| AVG Volume (30 Days) | 22.0K | ★ 535.0K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $285,413,000.00 | $31,804,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | $2.53 | $79.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 588.40 |
| 52 Week Low | $2.98 | $0.62 |
| 52 Week High | $18.00 | $1.70 |
Technical Indicators
Market Signals| Indicator | LVLU | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 35.65 |
| Support Level | $5.00 | $0.65 |
| Resistance Level | $5.66 | $0.68 |
| Average True Range (ATR) | 0.40 | 0.03 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 28.64 | 17.98 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.